Construction and application of anti-tumor drug prescription review decision-support system in a large general hospital
- VernacularTitle:某大型综合医院抗肿瘤药物审方决策系统的构建与应用
- Author:
Jing ZANG
1
;
Run GAN
2
;
Qi YANG
3
;
Yan CHEN
2
;
Cheng GUO
2
;
Jianping ZHANG
2
;
Fengqian LI
4
;
Quanjun YANG
2
Author Information
1. Dept. of Pharmacy，Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Shanghai 200233，China;Dept. of Pharmacy，Shanghai Eighth People’s Hospital，Shanghai 200233，China
2. Dept. of Pharmacy，Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Shanghai 200233，China
3. Dept. of Pharmacy，Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Shanghai 200233，China;Lingyun Community Health Service Center，Xuhui District in Shanghai，Shanghai 200237，China
4. Dept. of Pharmacy，Shanghai Eighth People’s Hospital，Shanghai 200233，China
- Publication Type:Journal Article
- Keywords:
anti-tumor drugs;
prescription review;
prescription review decision-support system;
rational drug use
- From:
China Pharmacy
2026;37(6):794-799
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To introduce the development of an intelligent prescription review decision-support system for anti-tumor drugs and assess its clinical application outcomes. METHODS Relevant data sources， including national and local pharmaceutical administration policies， clinical practice guidelines/consensus， hospital information systems data， and genetic testing results， were integrated. Adhering to the principles of structure， standardization and dynamic updating， a knowledge base covering chemotherapeutic， targeted and immunotherapeutic agents was constructed using a dual-dimensional modeling approach that combined “drug attributes” and “clinical contexts”. This knowledge base was then embedded into the hospital’s electronic medical order system to establish the prescription review decision-support system. The application and performance of the system were evaluated at Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. RESULTS A knowledge base containing 18 318 prescription review rules for anti-tumor drugs was constructed， and a closed-loop prescription review system was successfully established， encompassing pre-prescription real-time intervention， in-process interactive review， and post-prescription evaluation and analysis. From 2021 to 2024， the system generated a total of 57 879 alerts for prescriptions of five typical categories of anti-tumor drugs. For platinum-containing prescriptions， 22 577 alerts were generated， with Cisplatin for injection （lyophilized） being the most frequently alerted drug （13 445 alerts）， and “ototoxicity risk due to combined use” alerts remained high （7 682 alerts）. For methotrexate-containing prescriptions， 3 721 alerts were recorded， primarily related to “precaution-related issues” （76.4%， 2 843/3 721）. For doxorubicin-containing prescriptions， 17 301 alerts were triggered， primarily related to “dosage and administration” （14 315 alerts）. For human epidermal growth factor receptor 2-targeted agents-containing prescriptions， 1 007 alerts were issued， mostly related to “reimbursement restrictions” （956 alerts）. For programmed death-1/programmed death-ligand 1 inhibitors-containing prescriptions， the alerts increased year by year， totaling 13 273 alerts， primarily related to “inappropriate indication” （9 118 alerts）. Over the 4 years， the physician response rates to system alerts were 21.4%， 27.1%， 33.5% and 51.6%， respectively. CONCLUSIONS An intelligent decision-support system for anti-tumor drug prescription review， encompassing a closed-loop process of “real-time pre-event intervention， interactive in-event prescription review， post-event evaluation and analysis”， has been successfully constructed and implemented throughout the entire workflow. There is a discernible trend in this hospital， where the focus on monitoring anti-tumor drugs is shifting towards immunotherapy drugs. Additionally， the acceptance rate of physicians regarding prescription review opinions has been steadily increasing year by year.
